At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 114 enrolled
Drug / intervention
CLG561 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy
In Brief
A Phase 2 clinical trial evaluating CLG561, LFG316, and 1 other intervention for Geographic Atrophy. Completed, enrolled 114 participants.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of 12 (every 28 days) intravitreal (IVT) injections of CLG561 as a monotherapy and in combination with LFG316 as compared to sham in subjects with geographic atrophy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGeographic Atrophy
Countries--
CollaboratorsNovartis Institutes for BioMedical Research
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 2015
Enrollment StartSep 2015
Primary CompletionAug 2017
Study CompletionDec 2017
TodayJul 2026
First PostedAug 5, 2015
Enrollment StartSep 25, 2015
Primary CompletionAug 14, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 10.9 years ago
Interventions
CLG561drug
LFG316drug
Sham injectiondrug
Empty syringe (without a needle) placed against the eye